Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation

Human and Experimental Toxicology

Volumn 34, Issue 1, 2015, Pages 44-55

  Aher, J S ^a   Khan, S ^a   Jain, S ^a   Tikoo, K ^a   Jena, G ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

HDAC inhibitor; hepatic fibrosis; Hepatic stellate cell; thioacetamide; valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; COLLAGEN; GELATINASE A; THIOACETAMIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VALPROIC ACID; GLUTATHIONE; MMP2 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL ACTIVATION; CELL FUNCTION; CELL INFILTRATION; COMET ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER WEIGHT; MALE; NICK END LABELING; NONHUMAN; PATHOGENESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STELLATE CELL; THIOACETAMIDE INDUCED FIBROSIS; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; METABOLISM; ORGAN SIZE; PATHOLOGY; ULTRASTRUCTURE; WISTAR RAT;

RATTUS;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; COMET ASSAY; DNA DAMAGE; GLUTATHIONE; HEPATIC STELLATE CELLS; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MICROSCOPY, ELECTRON, TRANSMISSION; ORGAN SIZE; RATS, WISTAR; THIOACETAMIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VALPROIC ACID;

EID: 84919633061     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327114531992     Document Type: Article

References (46)

1. Arthur MJ. Collagenases and liver fibrosis. J Hepatol. 1995 ; 22: 43-48
2. Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Z Gastroenterol. 2007 ; 45: 43-50
3. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011 ; 6: 425-456
4. Muddu AK, Guha IN, Elsharkawy AM, et al. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol. 2007 ; 39: 695-714
5. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 2005 ; 25: 552-563
6. Ptak C, Petronis A. Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Pharmacol Toxicol. 2008 ; 48: 257-276
7. Mann DA, Mann J. Epigenetic regulation of hepatic stellate cell activation. J Gastroenterol Hepatol. 2008 ; 23 (Suppl 1). S108 - S111
8. Rombouts K, Knittel T, Machesky L, et al. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol. 2002 ; 37: 788-796
9. Komorowsky C, Ocker M, Goppelt-Struebe M. Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. J Cell Mol Med. 2009 ; 13: 2353-2364
10. Mannaerts I, Nuytten NR, Rogiers V, et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology. 2010 ; 51: 603-614
11. Van Beneden K, Geers C, Pauwels M, et al. Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol. 2011 ; 22: 1863-1875
12. Watanabe T, Tajima H, Hironori H, et al. Sodium valproate blocks the transforming growth factor (TGF)-beta1 autocrine loop and attenuates the TGF-beta1-induced collagen synthesis in a human hepatic stellate cell line. Int J Mol Med. 2011 ; 28: 919-925
13. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther. 2010 ; 335: 266-272
14. Van Beneden K, Geers C, Pauwels M, et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol Appl Pharmacol. 2013 ; 271 (2). 276-284
15. Niki T, Rombouts K, De Bleser P, et al. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology. 1999 ; 29: 858-867
16. Van Beneden K, Mannaerts I, Pauwels M, et al. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair. 2013 ; 6: 1
17. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994 ; 47: 332-372
18. Verrotti A, D'Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obesity Rev. 2011 ; 12: e32 - e43
19. Wagner PG, Welton SR, Hammond CM. Gastrointestinal adverse effects with divalproex sodium and valproic acid. J Clin Psychiatry. 2000 ; 61: 302-303
20. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Canc Treat Rev. 2008 ; 34: 206-222
21. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003 ; 22: 3411-3420
22. Rocchi P, Tonelli R, Camerin C, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005 ; 13: 1139-1144
23. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Canc. 2007 ; 97: 177-182
24. Rocca A, Minucci S, Tosti G, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Canc. 2009 ; 100: 28-36
25. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001 ; 20: 6969-6978
26. Khan S, Ahmad T, Parekh CV, et al. Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod Toxicol. 2011 ; 32: 385-394
27. Khan S, Jena GB. Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment schedule. Toxicol Int. 2013 ; 70: 68-76
28. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979 ; 582: 67-78
29. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 ; 193: 265-275
30. Singh NP, McCoy MT, Tice RR, et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988 ; 175: 184-191
31. Naziroglu M, Yurekli VA. Effects of antiepileptic drugs on antioxidant and oxidant molecular pathways: focus on trace elements. Cell Mol Neurobiol. 2013 ; 33: 589-599
32. Chong W, Li Y, Liu B, et al. Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study. J Trauma Acute Care Surg. 2012 ; 72: 347-354
33. Hu S, Hou JY, Wang HB, et al. The effect of valproic acid in alleviating early death in burn shock. Burns. 2012 ; 38: 83-89
34. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc. 2004 ; 37: 3-15
35. Gurvich N, Tsygankova OM, Meinkoth JL, et al. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Canc Res. 2004 ; 64: 1079-1086
36. Schmitt-Graff A, Kruger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 1991 ; 138: 1233-1242
37. Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2008 ; 103: 319-327
38. Ledda-Columbano GM, Coni P, Curto M, et al. Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am J Pathol. 1991 ; 139: 1099-1109
39. Okuyama H, Shimahara Y, Nakamura H, et al. Thioredoxin prevents thioacetamide-induced acute hepatitis. Comp Hepatol. 2004 ; 3 (Suppl 1). S6
40. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Canc Lett. 2008 ; 269: 7-17
41. Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology. 2003 ; 37: 87-95
42. Ahmad T, Shekh K, Khan S, et al. Pretreatment with valproic acid, a histone deacetylase inhibitor, enhances the sensitivity of the peripheral blood micronucleus assay in rodents. Mutat Res. 2013 ; 751: 19-26
43. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Canc Drug Targets. 2008 ; 8: 132-140
44. Inoue S, MacFarlane M, Harper N, et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004 ; 11 (Suppl 2). S193 - S206
45. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005 ; 11: 77-84
46. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology. 2006 ; 43: 425-434